<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584246</url>
  </required_header>
  <id_info>
    <org_study_id>3</org_study_id>
    <secondary_id>105362</secondary_id>
    <nct_id>NCT00584246</nct_id>
  </id_info>
  <brief_title>Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome</brief_title>
  <official_title>Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of Pregabalin (Lyrica) in treating patients
      with Restless Legs Syndrome (RLS) in a double-blind, placebo-controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn due to budget (personnel) limitations.
  </why_stopped>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International RLS Study Group Severity Scale (IRLS)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin (Lyrica)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin (Lyrica)</intervention_name>
    <description>50 - 150 mg po qhs for 2 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 - 150 mg po qhs for 2 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients with RLS diagnosed by a movement disorder specialist/ Sleep specialist .

          2. Patients must report some degree of pain which occurs on a regular basis.

          3. Age 18 years to 80 years.

          4. Women of child-bearing potential must use a reliable method of contraception and must
             provide a negative pregnancy test at entry into the study.

          5. Stable doses of all medications for 30 days prior to study entry and for the duration
             of the study.

          6. Willing and able to provide informed consent.

          7. Willing to comply with protocol. -

        Exclusion Criteria:

          1. Any illness that in the investigator's opinion preclude participation in this study.

          2. Pregnancy or lactation.

          3. Concurrent participation in another clinical study.

          4. Current treatment with a dopamine agonist (unless stopped at least 2 weeks prior to
             baseline).

          5. Dementia or other psychiatric illness that prevents the patient from giving informed
             consent (Mini Mental Status Exam score less than 24).

          6. Legal incapacity or limited legal capacity.

          7. Presence of severe renal disease BUN 50% greater than normal, Patients must have
             evidence from their PCP or Urologists of normal PSA and urodynamic tests within the
             last 12 month. Normal BUN levels should be within a range of 5 to 20 mg/ d L and
             creatinine between .7 and 1.4 mg/ d L. Labs will be requested from PCP.

          8. Presence of major hepatic impairment (Cirrhosis, Viral Hepatitis, Nonalcoholic
             Steatohepatitis, Wilson's disease, or Hemochromatosis). LFT must show non-clinically
             significant results (Albumin range 3.0-6.0; Alkaline phosphatase range 40-150; ALT
             range 0-55; AST range 5-34).

          9. Presence of severe daytime sleepiness.

         10. Present complaints of somnolence, dizziness, blurred vision, bleeding tendencies,
             cardiac abnormalities.

         11. Patients taking dopamine agonists for any condition other than RLS. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa A Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of South Florida</investigator_affiliation>
    <investigator_full_name>Theresa Zesiewicz, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Restless legs syndrome</keyword>
  <keyword>RLS</keyword>
  <keyword>Pregabalin</keyword>
  <keyword>Lyrica</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

